You are here: Home » Markets » News
Business Standard

MARKET WRAP: Sensex ends 19 pts down, Nifty at 10,768; Sun Pharma up 8%

Sun Pharma surged over 8%, while Dr. Reddy ended nearly 5% higher on the BSE.

SI Reporter  |  New Delhi 

Markets, Stocks, BSE, NSE, Trade
Photo: Shutterstock.com

Sun Pharma ends 8% on the NSE: Nifty Pharma index ends 4.26% higher. Top gainers: COMPANY LATEST PREV CLOSE GAIN() GAIN(%) SUN PHARMA.INDS. 528.25 488.75 39.50 8.08 LUPIN 810.05 767.35 42.70 5.56 DR REDDY'S LABS 2062.90 1964.95 97.95 4.98 AUROBINDO PHARMA 572.35 547.75 24.60 4.49 GLENMARK PHARMA. 556.75 536.65 20.10 3.75 Sectoral Trend BSE Sensex: Sun Pharma, Dr Reddy among top gainers of the day Market at close   The S&P BSE Sensex ended at 35,444, down 19 points while the broader Nifty50 index settled at 10,768, down 1 points. Reliance Industries rises for the eighth straight trading day Shares of Reliance Industries (RIL) have moved higher by 1.5% to Rs 986 per share, rebounding 2.6% from their intra-day low of Rs 961 on the BSE. READ MORE  

Benchmark indices trimmed their morning losses and ended flat on Friday even as yields on the 10-year government bonds hit over 8% in the opening session today, first time since May 2015, but soon declined.

The S&P BSE Sensex ended at 35,444, down 19 points while the broader Nifty50 index settled at 10,768, down 1 points.

Among individual stocks, Sun Pharma surged over 8%, while Dr. Reddy ended nearly 5% higher on the BSE.

Among sectoral indices, the Nifty Pharma index rose 4.26% today led by a rise in the shares of Sun Pharmaceutical Industries, Lupin and Dr. Reddy's Laboratories.

Investors also continued to react to Reserve Bank of India's (RBI) first rate hike since 2014, while maintaining a neutral stance. 

GLOBAL MARKETS

World stocks slipped on Friday as expectations of trade tensions dominating this weekend's summit of G7 countries, along with renewed talk of monetary tightening by major central banks, weighed on risk sentiment.

MSCI's broadest index of Asia-Pacific shares outside Japan fell 1.1 per cent after six straight sessions of gains took it to its highest since mid-March. It was on track for a weekly gain of more than 1 per cent.

Chinese shares slipped, with the blue-chip Shangai-Shenzhen index down 1.7 per cent and Hong Kong's Hang Seng declining 1.5 per cent.

Japan's Nikkei average and South Korea's KOSPI were off 0.6 per cent and 0.8 per cent, respectively.

(with inputs from Reuters)

First Published: Fri, June 08 2018. 15:30 IST
RECOMMENDED FOR YOU

MARKET WRAP: Sensex ends 19 pts down, Nifty at 10,768; Sun Pharma up 8%

Sun Pharma surged over 8%, while Dr. Reddy ended nearly 5% higher on the BSE.

Benchmark indices trimmed their morning losses and ended flat on Friday even as yields on the 10-year government bonds hit over 8% in the opening session today, first time since May 2015, but soon declined.

The S&P BSE Sensex ended at 35,444, down 19 points while the broader Nifty50 index settled at 10,768, down 1 points.

Among individual stocks, Sun Pharma surged over 8%, while Dr. Reddy ended nearly 5% higher on the BSE.

Among sectoral indices, the Nifty Pharma index rose 4.26% today led by a rise in the shares of Sun Pharmaceutical Industries, Lupin and Dr. Reddy's Laboratories.

Investors also continued to react to Reserve Bank of India's (RBI) first rate hike since 2014, while maintaining a neutral stance. 

GLOBAL MARKETS

World stocks slipped on Friday as expectations of trade tensions dominating this weekend's summit of G7 countries, along with renewed talk of monetary tightening by major central banks, weighed on risk sentiment.

MSCI's broadest index of Asia-Pacific shares outside Japan fell 1.1 per cent after six straight sessions of gains took it to its highest since mid-March. It was on track for a weekly gain of more than 1 per cent.

Chinese shares slipped, with the blue-chip Shangai-Shenzhen index down 1.7 per cent and Hong Kong's Hang Seng declining 1.5 per cent.

Japan's Nikkei average and South Korea's KOSPI were off 0.6 per cent and 0.8 per cent, respectively.

(with inputs from Reuters)

image
Business Standard
177 22